Cancer, at its most fundamental level, is a disease of the cell cycle. Normal cells follow a tightly controlled sequence of growth, DNA copying, and division, with built-in checkpoints that halt the process if something goes wrong. Cancer cells break free of those controls. They divide when they shouldn’t, skip safety checks, ignore damage to their DNA, and never stop multiplying. Understanding how the cell cycle normally works, and exactly where it breaks down, is the clearest way to understand what cancer actually is.
How the Normal Cell Cycle Works
Every cell in your body that divides goes through four main phases. In G1 (the first “gap” phase), the cell grows and prepares to copy its DNA. In S phase (synthesis), the cell duplicates its entire set of chromosomes. In G2 (the second gap phase), the cell checks the copied DNA for errors and prepares for division. In M phase (mitosis), the cell physically splits into two daughter cells, each with a complete set of chromosomes.
Between these phases sit checkpoints, molecular gates that only open when conditions are right. The most important one is the restriction point, which sits in late G1, roughly two to three hours before DNA synthesis begins. Once a cell passes the restriction point, it’s committed to dividing. Before that point, the cell can still back out and enter a resting state called G0, where most of your body’s cells spend their time. A second major checkpoint at the G2/M boundary ensures damaged DNA doesn’t get carried into division. A third, the spindle assembly checkpoint during M phase, makes sure chromosomes are properly lined up before the cell splits apart.
These checkpoints are not optional. They are enforced by specific proteins that act as brakes on the cycle. When those brakes fail, cancer becomes possible.
The Restriction Point: Where Cancer Begins
In 1974, researchers comparing the growth of cancer cells and normal cells discovered that cancer cells had lost their restriction point. This turned out to be one of the defining differences between normal and cancerous cell division.
In a healthy cell, passing the restriction point requires external growth signals called mitogens. These signals activate a chain reaction: a receptor on the cell surface triggers a protein called Ras, which fires off a cascade of signals that ultimately push the cell through G1. Two signaling pathways divide the work. The Ras/MAPK pathway controls early G1, while the PI3K/AKT/mTOR pathway handles late G1. Both must be active for the cell to commit to division.
Cancer cells short-circuit this requirement. Mutations in Ras (one of the most common cancer-driving mutations) lock the protein in its “on” position, flooding the cell with growth signals it never received from outside. The cell no longer needs to be told to divide. It tells itself.
The Two Master Brakes: Rb and p53
Two proteins do most of the heavy lifting when it comes to stopping the cell cycle at the right moments. Both are tumor suppressors, meaning their job is to prevent uncontrolled growth. When both are lost, the cell cycle runs without meaningful oversight.
The Rb Protein
The retinoblastoma protein (Rb) acts as a gatekeeper at the G1/S transition. In its active form, Rb physically blocks a group of transcription factors called E2F from turning on genes needed for DNA synthesis. The cell cannot enter S phase while Rb is doing its job.
To pass through, the cell must gradually deactivate Rb through a process called phosphorylation. Proteins called cyclin D paired with their partner enzymes (CDK4 and CDK6) start this process, and cyclin E paired with CDK2 finishes it. Once Rb is fully phosphorylated, it releases E2F, which switches on the genes for DNA replication. A family of four inhibitor proteins normally keeps CDK4/6 in check, preventing premature Rb inactivation.
In cancer, this system breaks at multiple points. Cyclin D1 is overexpressed in many human tumors, flooding the cell with the very proteins that deactivate Rb. In other cancers, Rb itself is absent or nonfunctional. Either way, the gate swings open permanently. The cell enters S phase without proper authorization.
The p53 Protein
If Rb is the gatekeeper, p53 is the emergency brake. When a cell’s DNA is damaged, p53 activates and halts the cycle so repairs can be made. If the damage is too severe, p53 triggers programmed cell death (apoptosis) or forces the cell into permanent retirement (senescence). It does this primarily by switching on a protein called p21, which directly blocks the cyclin-CDK complexes needed to advance the cycle.
The TP53 gene is mutated or deleted in roughly half of all human cancers, across at least 52 different tumor types. When p53 is lost, damaged DNA no longer triggers a stop signal. Cells with broken chromosomes, missing genes, or dangerous mutations continue dividing and passing those errors to their daughter cells, accelerating the accumulation of further mutations.
How Each Phase Goes Wrong
Cancer doesn’t just break one checkpoint. Different tumors exploit vulnerabilities at different points in the cycle.
In G1, the loss of a protein called p16 (one of the inhibitors that keeps CDK4/6 in check) lets cells blow past the restriction point. Aberrant cyclin D1 expression has been reported across many cancer types, effectively overriding the normal requirement for growth factor signals.
At the G1/S transition, cyclin E is amplified or overexpressed in some breast cancers, colon cancers, and certain leukemias. Another protein called Cdc25A, which normally fine-tunes the timing of this transition, is overexpressed in some tumors, allowing CDK-cyclin complexes to activate on an unscheduled basis.
During S phase, cells normally have mechanisms to suppress DNA replication if damage is detected. Cancer cells that have lost p53 or other checkpoint proteins replicate damaged DNA without hesitation, locking in mutations that would otherwise be caught and repaired.
At the G2/M boundary, normal cells keep the key mitotic enzyme (CDK1-cyclin B) in an inhibited state until DNA integrity is verified. Cancer cells with defective G2 checkpoints enter mitosis carrying unrepaired damage.
During M phase itself, the spindle assembly checkpoint ensures every chromosome is properly attached to the spindle before the cell splits. This checkpoint works by preventing the premature separation of duplicated chromosomes. When it fails, chromosomes are distributed unevenly between daughter cells, a condition called aneuploidy. Abnormal chromosome numbers are a hallmark of aggressive cancers and drive further genetic instability, creating a snowball effect where each division produces cells with increasingly disordered genomes.
How Cancer Cells Avoid Running Out of Divisions
Even after escaping all these checkpoints, cancer cells face one more barrier. Normal cells can only divide a limited number of times before their telomeres, protective caps on the ends of chromosomes, become too short. At that point, the cell stops dividing permanently.
Cancer cells solve this problem by reactivating an enzyme called telomerase, which rebuilds telomeres after each division. Telomerase is normally silent in adult cells but is frequently switched back on in tumors through genetic and chemical changes to the gene that encodes it. A smaller subset of cancers uses a different strategy called Alternative Lengthening of Telomeres (ALT), which maintains telomere length through a recombination-based mechanism. Some tumors may even grow large enough before telomere erosion becomes lethal, bypassing the need for either mechanism entirely. Regardless of the strategy, the result is the same: replicative immortality, one of the classic hallmarks of cancer.
Treatments That Target the Cell Cycle
Because cancer is fundamentally a cell cycle problem, some of the most effective modern therapies work by reinstating the brakes that cancer cells have lost. The clearest example is a class of drugs that block CDK4 and CDK6, the enzymes that normally deactivate the Rb protein in G1.
Three of these drugs are now approved for treating hormone receptor-positive, HER2-negative breast cancer: palbociclib (approved 2015), ribociclib (approved 2017), and abemaciclib (approved 2017). They work by preventing cancer cells from phosphorylating Rb, effectively locking the G1 gate shut and stopping the cell from entering S phase. Abemaciclib is particularly potent against CDK4, blocking its activity at very low concentrations. Since 2021, abemaciclib has also been approved for early-stage breast cancer patients at high risk of recurrence, not just those with metastatic disease.
These drugs represent a broader principle in cancer treatment: rather than poisoning all dividing cells (as traditional chemotherapy does), targeted therapies aim to restore the specific checkpoint that a particular cancer has broken. The better we understand which cell cycle controls a tumor has lost, the more precisely treatment can be matched to the biology driving that tumor’s growth.